Asunto(s)
Supervivencia de Injerto , Heparina/uso terapéutico , Terapia de Inmunosupresión , Trasplante de Piel/inmunología , Administración Oral , Animales , Linfocitos B/inmunología , Heparina/administración & dosificación , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C3H , Linfocitos T/inmunología , Trasplante HomólogoRESUMEN
Recent data suggest that low dose subcutaneous heparin treatment inhibits cell-mediated immune reactions. Administering heparin by routes other than injection would be both convenient and safe clinically. The results of this study show that heparin can be absorbed from the digestive tract of mice and cause disturbances of coagulation, which occur after a prolonged administration of its higher doses. Moreover, oral heparin has an immunosuppressive action, as evidenced by an ability of its lower doses to slow down the process of rejection of both primary and secondary skin allografts in mice. The immunosuppressive effect of heparin is unrelated to its anticoagulant activity.
Asunto(s)
Supervivencia de Injerto/efectos de los fármacos , Heparina/administración & dosificación , Trasplante de Piel/inmunología , Administración Oral , Animales , Inmunosupresores/administración & dosificación , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C3HRESUMEN
NTG in higher doses inhibits specific antibody responses in mice when given after but not prior to antigen. The drug also causes suppression of polyclonal humoral responses but to a lesser extent than other alkylating agents.
Asunto(s)
Formación de Anticuerpos/efectos de los fármacos , Mecloretamina/farmacología , Animales , Antígenos/administración & dosificación , Linfocitos B/efectos de los fármacos , Linfocitos B/inmunología , Eritrocitos/inmunología , Inmunosupresores/farmacología , Mecloretamina/administración & dosificación , Ratones , Ratones Endogámicos BALB C , Ovinos , Bazo/citología , Bazo/efectos de los fármacos , Bazo/inmunologíaRESUMEN
The effect of FK506 and cyclosporine on NK and ADCC activity was evaluated. Cytotoxic cells mediating both activities are resistant to FK506. In contrast, preincubation of ADCC and NK effectors with cyclosporine decreases their cytotoxic potential, while adding the drug to the assays is without effect.
Asunto(s)
Antibacterianos/farmacología , Citotoxicidad Celular Dependiente de Anticuerpos/efectos de los fármacos , Ciclosporinas/farmacología , Inmunosupresores/farmacología , Células Asesinas Naturales/efectos de los fármacos , Humanos , Células Asesinas Naturales/inmunología , TacrolimusRESUMEN
Donor-specific blood transfusions are unable to prolong mouse allogeneic skin allograft survival. Likewise, only a high dose of cyclophosphamide may be efficacious. In contrast, the combination of pretransplant transfusions with posttransplant injections of cyclophosphamide is highly efficacious.
Asunto(s)
Transfusión Sanguínea , Ciclofosfamida/administración & dosificación , Refuerzo Inmunológico de Injertos , Trasplante de Piel/inmunología , Animales , Ciclofosfamida/farmacología , Femenino , Supervivencia de Injerto/efectos de los fármacos , Ratones , Ratones Endogámicos A/inmunología , Ratones Endogámicos BALB C/inmunología , Cuidados Preoperatorios , Trasplante HomólogoAsunto(s)
Supervivencia de Injerto/efectos de los fármacos , Heparina/farmacología , Inmunosupresores/farmacología , Trasplante de Piel , Animales , Relación Dosis-Respuesta a Droga , Heparina/administración & dosificación , Inmunosupresores/administración & dosificación , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BLRESUMEN
The ability of FK506 and cyclosporine to prolong mouse skin allograft survival when given alone and in combination was studied during primary and secondary responses. The drugs were efficient immunosuppressants of both types of anti-graft responses but--as reported earlier--much lower FK506 doses were required to produce those effects. Both agents synergized when administered together during primary responses but not secondary responses. This suggests that the combination treatment may be less successful in a presensitized host, a finding with potential clinical application.
Asunto(s)
Antibacterianos/farmacología , Ciclosporinas/farmacología , Supervivencia de Injerto/efectos de los fármacos , Memoria Inmunológica/efectos de los fármacos , Trasplante de Piel/inmunología , Animales , Sinergismo Farmacológico , Inmunosupresores , Masculino , Ratones , Ratones Endogámicos A , Ratones Endogámicos BALB C , TacrolimusRESUMEN
The macrolide antibiotic FK-506 causes a strong inhibition of human T and B cell proliferation in vitro in concentrations 100-fold lower than cyclosporine (CsA). However, B cell activation appears to be less sensitive to the immunosuppressive action of FK-506 than T cell responses. There was no indication of a synergistic interaction of the two agents. In contrast, CsA added together with FK could counteract the immunosuppressive activity of the latter drug.
Asunto(s)
Antibacterianos/farmacología , Linfocitos B/efectos de los fármacos , Ciclosporinas/farmacología , Inmunosupresores/farmacología , Activación de Linfocitos/efectos de los fármacos , Linfocitos T/efectos de los fármacos , Linfocitos B/inmunología , Células Cultivadas , Humanos , Linfocitos T/inmunología , TacrolimusRESUMEN
This study is a continuation of our previous work demonstrating the potentiating activity of TFX on cyclophosphamide-induced immunosuppression. Mice primed with TFX subsequently received cyclophosphamide and antigen and their B cell responses were evaluated with an aid of antigen-specific and reverse plaque forming cell assay. Cyclophosphamide-dependent inhibition of immunoglobulin synthesis was significantly stronger in mice pretreated with TFX than in controls. However, the synergistic immunosuppressive action of TFX with cyclophosphamide was evident only when polyclonal but not specific humoral response was studied.